David K. Lee, CEO of Servier Pharmaceuticals, shared a post on LinkedIn:
“As I departed the J.P. Morgan Healthcare Conference last week, I returned to Boston feeling energized by the momentum and grounded by the shared sense of purpose and responsibility I felt.
This year, JPM was less about splashy dealmaking or major announcements and more about what leads to secure, long-term stability: disciplined execution, resilient pipelines, and thoughtful capital allocation. That focus resonated deeply with me.
What stood out most was the clarity around the scale of the work ahead and the trust patients place in all of us. For people living with difficult-to-treat diseases, especially those still waiting for meaningful treatment options, progress cannot wait. That reality sharpens our purpose and reinforces why our work matters.
Over the past two years, Servier has evolved in meaningful ways. We have expanded our footprint in oncology, grown a promising pipeline in neurology, and opened our doors more widely to collaboration. What has not changed is how or whywe do this work. Our responsibility to serve patients is not theoretical. It’s a daily reminder that we all must move forward with urgency and purpose.
We plan to do just that. Here’s what lies ahead for Servier in 2026:
Building on Foundational Strength in Oncology
Oncology will continue to be a core driver in 2026. Servier’s leadership in targeted therapies positions us to accelerate our pipeline and the delivery of meaningful treatments for more patients living with cancer. Our experience navigating complex biology in oncology motivates us to continue pursing even more ambitious targets and indications, and we expect to advance our portfolio while fueling sustainable growth and expanding our reach in high-unmet-need cancers.
Expanding Into Neurology with Purpose
One of the most exciting horizons for Servier is our growth in neurology.
For us, addressing rare neurological diseases is not just a R&D challenge; it is a responsibility to the small patient populations who have long been underserved by therapeutic innovation. Progress in research and innovation in this area offers the potential to fuel breakthroughs and ensure that every patient receives care, regardless of how rare their condition may be.
Last year, we acquired our first asset in neurology targeting rare neurodevelopmental disorders. The latest asset joins a robust neurology pipeline that currently includes 15 programs spanning early discovery through clinical development. Each reflects our ambition to deliver meaningful clinical impact and long-term value in the rare disease space.
Neurology represents not just a new chapter in our pipeline, but a test of how we leverage our oncology expertise and shared biology across therapeutic areas.
Partnerships as a Strategic Imperative
Open innovation and strategic partnerships will remain central to our strategy. Much of our growth over the past eight years has come through thoughtful partnering with key biotech innovators, allowing Servier to amplify our internal capabilities and accelerate access to cutting-edge science.
JPM reinforced a simple truth: strong collaboration with the right partners translates to medicines that change patient lives. As we look ahead, we will continue to pursue collaborations that extend our reach and deepen our impact.
Leveraging AI to Shape What Comes Next
Last week, my Servier colleagues and I had the opportunity to spend time with tech leaders, VCs, and breakthrough entrepreneurs at Google and Microsoft, stepping out of the JPM whirlwind to listen, learn, and think deeply about what comes next.
As we continue to deepen Servier collaborationsacross pioneering med-tech partners like OWKIN, Aitia, Insilico Medicine, and Iktos, we’re committed to strengthening our understanding of tech innovation and AI capabilities at every turn. Learning from the leaders at the forefront of that progress is crucial, and our teams will continue to invest in these key partnerships and opportunities to ensure we’re on the front line of what’s ahead: an AI-driven future for R&D that moves faster, uncovers new possibilities, and delivers meaningful change for patients.
Delivering for Patients
At the heart of Servier’s roadmap for the year ahead is a commitment I take personally: turning scientific promise into meaningful progress for the patients we serve. Whether we are expanding access to our medicines or forging high-impact partnerships, every decision is guided by that responsibility.
As we move into 2026, I remain confident in our teams and anchored in scientific rigor. The work ahead is demanding, but it is work that matters, and we are ready for it.”
More posts featuring David K. Lee.